vivoPharm expands, TGR contracts
Wednesday, 06 February, 2008
Adelaide-based contract research organisation vivoPharm is to open a European subsidiary in Germany after receiving an injection of venture capital funds.
vivoPharm Europe will be based in Munich and headed by Dr Katja Wosikowski. It aims to develop new business and maintain relationships with existing customers in Austria, Germany, Switzerland, Spain and Norway.
vivoPharm was established in 2003 and offers integrated preclinical services to the biotechnology and pharmaceutical industries.
It received $1 million in venture capital from the South Australian Life Sciences Advancement Fund, managed by Terra Rossa Capital.
Another Adelaide biotech, TGR BioSciences, has appointed former PricewaterhouseCoopers (PwC) life sciences specialist Andrew Sneddon to its board.
TGR specialises in drug discovery for oral and gastrointestinal health and skin and tissue repair.
Organoid platform enables closer study of bat-borne viruses
Reconstructing bat organ physiology in the lab lets scientists explore how zoonotic viruses work...
Global study finds 250 genes linked to OCD
Researchers say they have found the genes linked to obsessive compulsive disorder (OCD), after...
TGA approves therapy for paediatric growth hormone deficiency
The TGA has approved SKYTROFA as a treatment for growth failure in children and adolescents aged...
